Deal establishes Regnology as a central partner in U.S. regulatory modernization, extending reach to over 4,000 financial institutions

AGOURA HILLS, Calif. & FRANKFURT, Germany–(BUSINESS WIRE)– Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced it has entered into a definitive agreement to acquire Fed Reporter, the market-leading U.S. provider of regulatory reporting solutions for financial institutions of all sizes, including banks, credit unions, and bank holding companies.

The acquisition marks a pivotal milestone in Regnology’s U.S. expansion, creating the most comprehensive regulatory reporting coverage across the American financial landscape and extending its reach to more than 4,000 institutions from global banks to community lenders. By combining a proven, cloud-first, agentic-first technology foundation with deeply embedded local expertise, Regnology is uniquely positioned to support more efficient, transparent, and data-driven reporting, while strengthening alignment between financial institutions and supervisory authorities.

“This is the next step in our U.S. strategy,” said Rob Mackay, CEO of Regnology. “We’ve built strong capabilities and relationships across the market. Fed Reporter extends that reach into the US financial landscape, completing our coverage from Wall Street to Main Street. Our goal is to be a long-term partner in regulatory modernization.” Mackay added: “By combining trusted, mission-critical solutions with continued innovation, including more intelligent and automated reporting, we help institutions and regulators manage complexity, improve data quality, and move forward with confidence.”

Alexander Grimm, Head of Americas at Regnology, commented: “We are excited to welcome the highly respected Fed Reporter team into our organization. Their expertise and client relationships are unmatched, and together we combine deep local knowledge with global technology to better serve the entire U.S. market.”

Fed Reporter will continue to operate as a trusted, purpose-built platform for financial institutions. Regnology’s priority is full business continuity: the team, solutions, and service clients rely on will remain unchanged. Over time, clients will benefit from the scale, investment capacity, and innovation capabilities of a global RegTech leader, reinforcing Regnology’s position as a stable, long-term partner in the market.

“This is a strong step forward for our clients and team” said Bruce Gall, CEO of Fed Reporter. “We will continue to deliver the simplicity and expert support our clients trust, now backed by the scale and long-term vision of Regnology.”

This transaction represents the capstone of Regnology’s U.S. expansion, following earlier strategic acquisitions that established strong capabilities in broker-dealer reporting and enterprise-grade solutions for global institutions.

The addition of Fed Reporter’s deeply embedded “last-mile” reporting capabilities further strengthens the breadth and depth of Regnology’s U.S. offering, enhancing its ability to connect upstream data, reporting processes, and final submission, while supporting the evolving needs of both financial institutions and supervisory authorities.

The transaction is subject to customary regulatory approvals and is expected to close in the coming months.

About Fed Reporter

Fed Reporter is a market-leading provider of regulatory reporting software and services for U.S. banks, credit unions, and bank holding companies, serving over 4,300 institutions.

About Regnology

Regnology is a recognized leader in regulatory, risk, tax, and finance reporting technology— connecting regulators and the regulated across more than 100 countries. Our unique position enables us to span the full spectrum of industry needs, delivering solutions that address both oversight and compliance requirements to a broad range of clients, including global Tier 1 banks, local and regional institutions, corporates, insurers, and authorities.

For more information about Regnology, connect with us on LinkedIn and X.

Visit our website: www.regnology.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701405645/en/

Contacts

Mireille Adebiyi – Chief Marketing Officer

Email: mireille.adebiyi@regnology.net

• Ant International is developing around 1,500 talents in Kuala Lumpur, with more than half in tech-related roles, supporting the company’s global innovations and business growth
• Spending by Alipay+ partners via the DuitNow national QR increased more than 60%, driving travel-led economic impact as the country celebrates Visit Malaysia 2026
• Since launching in January 2026 with TNG Digital, Ant International’s EPOS360 AI-as-a-Service platform now supports more than 14,000 Malaysian SMEs

KUALA LUMPUR, Malaysia–(BUSINESS WIRE)– Ant International today officially opened its Global Development Centre (GDC) in Kuala Lumpur, deepening its long-term commitment to Malaysia and Southeast Asia, and strengthening the country’s role as a strategic hub for global innovation, digital talent, and next-generation financial technology. The unveiling ceremony was officiated by the Prime Minister of Malaysia, YAB Dato’ Seri Anwar Ibrahim.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701982923/en/

L to R: Datuk Fabian Bigar, Secretary General to Ministry of Digital, YB Senator Dato’ Seri DiRaja Dr. Zambry bin Abd Kadir, Minister of Higher Education, YAB Dato’ Seri Anwar Bin Ibrahim, Prime Minister of Malaysia, Cyril Han, CEO of Ant Group, Peng Yang, CEO of Ant International

Ant International’s GDC is located at The Exchange 106, within TRX, Malaysia’s dedicated international financial centre.

Cyril Han, CEO of Ant Group said, “With a visionary leadership and a vibrant business and tech community, Malaysia is on the way to becoming a leading regional and global hub for digital and AI innovation. In the next 6 to 12 months, the agentic AI revolution will be in full swing, bringing about a revolution in commerce that we need to prepare for now, to ensure it drives both business growth and social development. Ant has many deep and long-term partnerships in Malaysia and the region, and with the unveiling of the Ant International Global Development Centre in Kuala Lumpur, we stand ready to support the AI Nation 2030 vision and digitalisation of Malaysia.”

Peng Yang, CEO of Ant International said, “Ant International’s development evolves around the ‘6T’ sustainable development strategy: facilitating global travel, empowering global trade, promoting robust growth, driving innovation through technology, nurturing digital talent, and building a trustworthy digital ecosystem. This aligns perfectly with Malaysia’s national agenda of promoting digital transformation and stimulating the vitality of micro, small and medium-sized enterprises. We are committed to long-term investments into growing world-calibre innovators as well as AI commerce solutions from Malaysia. ”

Developing Next-Gen Innovators, Building from Malaysia

The GDC represents another milestone in Ant International’s journey in Malaysia. It reflects the company’s belief that world-class innovation can be developed in Malaysia for global markets, by creating high-value employment opportunities, nurturing local talent and collaborating with public and private sector partners.

Ant International has created around 1,500 fintech roles in Malaysia, with more than 50 percent serving in technology roles, contributing to Ant International’s global businesses in AI, payments, SME digitalisation and financial technology.

Today, around half of its tech team are recent graduates, from across more than 30 universities in Malaysia, as the company collaborates with local partners like the Malaysia Digital Economy Corporation (MDEC), to develop the next generation of innovators.

Ant International will also deepen its collaboration with the Malaysian government and local universities, including with the Ministry of Higher Education to explore strategic partnerships, to co-develop more FinAI talents through hackathons, trainings, and curated curricula that strengthen educational pathways and power Malaysia’s digital economy development and growth.

Deepening Partnerships to Drive Malaysia’s Digital Economy and AI Developments

The GDC builds on Ant International’s longstanding partnerships with leading Malaysian organisations that have helped advance digital transformation, financial inclusion and cross-border connectivity.

Together with CIMB and TNG Digital, Ant International has supported the development of Touch ‘n Go eWallet since 2017, which today serves over 26 million consumers and businesses and underpinning Malaysia’s vibrant digital ecosystem. Through Ant International’s AI suite, including its GenAI Cockpit and AI travel agent, TNG Digital makes AI-powered everyday services accessible to its users.

Through Alipay+, Ant International’s unified wallet gateway, and its partnership with PayNet, Malaysia’s national payment network, international travellers can use their home e-wallets and bank apps to pay seamlessly at millions of merchants across Malaysia. As Malaysia celebrates Visit Malaysia 2026, the partnership is delivering tangible economic impact: in the first half of 2026, more than 600,000 merchants, primarily SMEs, received payment from an Alipay+ partner — up more than 70% year-on-year. Total traveller spending via DuitNow rose more than 60%, with Alipay+ being the largest contributor to inbound QR transactions in Malaysia. In the next step of the partnership, Malaysian payment apps supported by PayNet will be able to making payments at over 150 million merchants in more than 220 markets connected to Alipay+.

Ant International’s merchant solutions — Antom and 2C2P — are helping Malaysian businesses reach global customers and enabling Malaysian consumers connect to international brands, growing its digital merchant base by nearly 60% and processing more than 50% more transactions year-on-year.

The company now supports 300+ payment methods in over 220 markets, including all card schemes, 50 mobile payment partners and more than 10 national QR systems

Looking ahead, Ant International and CIMB are exploring next-generation financial infrastructure together, including tokenised deposits and innovative treasury solutions designed to enhance cross-border payment efficiency and liquidity management — building toward Malaysia’s ambition to become a leading global payments and treasury hub.

Powering Malaysian SME Digitalisation and Global Growth Opportunities

The GDC opening comes alongside a growing suite of solutions Ant International is deploying to support Malaysian businesses.

In January 2026, in partnership with TNG Digital, Ant International launched EPOS360 in Malaysia — an AI-as-a-Service platform that gives SMEs access to digital POS management, payments, banking, credit financing and growth tools in one place. EPOS360 now serves over 14,000 SMEs across Malaysia.

WorldFirst, Ant International’s global accounts service provider, obtained in-principle approval from Bank Negara Malaysia to operate under a Class A Money Services Business in 2025, enabling it to offer cross-border financial services — including global collections, payments, currency exchange and fund management — to Malaysian businesses expanding internationally. A local operations team is being established, with a full launch expected soon.

Through Bettr, Ant International aims to extend more inclusive financial services to underserved groups like gig workers and micro-enterprise owners. In 2026, Bettr partnered with Muslim Pro to provide Shariah-compliant financial enablement and flexibility for Malaysian Muslims with robust privacy protection, and its structure has been endorsed by Masryef Advisory Sdn. Bhd. and SEDANIA As-Salam Capital to ensure full alignment with Islamic financial principles.

For enterprise partners, Ant International’s AI capabilities are already delivering results: by leveraging its open-sourced AI FX model, AirAsia reduced foreign exchange-related costs by 40%.

“Malaysia has been an important part of our journey, and we believe its role will continue to grow. Together with our partners, we are building technologies, capabilities and opportunities from Malaysia and beyond, towards a more intelligent, connected and inclusive ecosystem,” added Yang.

The launch was also attended by YB Senator Dato’ Seri DiRaja Dr. Zambry bin Abd Kadir, Minister of Higher Education.

About Ant International

Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701982923/en/

Contacts

Media Contact:
Ant International

pr@ant-intl.com

• Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization
• Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback
• Regulatory filings in other territories are ongoing and remain on track

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland–(BUSINESS WIRE)– Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed.

The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority.

The observations do not impact approvals, launches, or regulatory reviews in other International markets.

Global launches progressing on track

As of today, Relfydess is approved in 33 markets and already launched in more than 20, including in Europe, the United Kingdom, the Middle East, Asia, and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback. Since 2022, this Galderma manufacturing site has completed 10 inspections from key regulatory authorities from around the world serving as the basis for International Relfydess launches. Regulatory filings in other territories are ongoing and remain on track.

Building a dermatology powerhouse

Galderma remains on a clear path to become the world’s undisputed dermatology powerhouse spanning the full spectrum of fast-growing markets across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

In Injectable Aesthetics, Galderma is firmly positioned on a trajectory to global leadership – not only in sales and market share, but also in innovation – supported by fully integrated in-house capabilities across discovery, research, development, manufacturing and commercialization of best-in-class products.

We will continue to build on this momentum through our robust pipeline, expanding the number of early-stage assets under development. Galderma leads the industry in the number of active aesthetic development programs, further reinforcing its leadership position in the U.S. and globally.

Galderma has the largest and most innovative Injectable Aesthetic portfolio on the market. Given our strong market position, we believe we are exceptionally well placed to capitalize on opportunities in this fast-growing market.

About Relfydess (relabotulinumtoxinA)

Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity. PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, creating a product that enables up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months. Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630345734/en/

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

MILAN–(BUSINESS WIRE)– Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders.

The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting discounts and commissions.

Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, Intesa Sanpaolo (IMI CIB Division), UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 30, 2026. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering, when available, may be obtained from:

• Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1 (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com;
• J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or
• Allen & Company LLC, Attention: Prospectus Department, 711 Fifth Avenue, 9th floor, New York, NY 10022, by telephone at +1 (212) 339-2220, or by email at allenprospectus@allenco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and does not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Certain statements contained in this press release constitute forward-looking statements, including with respect to the closing of the IPO. Management has based these forward-looking statements on its current expectations, assumptions, estimates, and projections. While they believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause Bending Spoons’ actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, Bending Spoons assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

About Bending Spoons

Bending Spoons is built on the conviction that operational excellence enables efficient growth through acquisitions. It acquires digital businesses, implements deep transformations and ongoing optimizations to sustainably expand earnings, and reinvests in additional acquisitions, thereby continuing the compounding cycle. The company has executed this strategy for more than a decade and, to date, has never sold a material business.

Bending Spoons strives to envision the most successful version of an acquired business, and works to close the gap between its current state and that vision as quickly and completely as possible. The transformation is typically deep and entails reorganizing teams, overhauling technology, redesigning user interfaces, accelerating product development, and enhancing marketing and monetization. AI is often both a central component of the vision and a key tool in implementing the transformation.

Bending Spoons’ performance is driven by its Platform — comprising its people, proprietary technologies, and proprietary data — and reflects an intense focus on achieving exceptional talent density, cultural strength, and technical capabilities.

Bending Spoons’ main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer. In March 2026, the company served over 500 million monthly active users and more than 9 million monthly paying customers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630780689/en/

Contacts

For further information please contact:


Christy Keenan

Bending Spoons S.p.A.

ck@bendingspoons.com

Darren McDermott

Brunswick Group U.S.

bendingspoonsUS@brunswickgroup.com

HAMILTON, Bermuda–(BUSINESS WIRE)– Sixth Street, a leading global investment firm, today announced that investment vehicles managed or advised by Sixth Street have entered into a definitive agreement to acquire a majority stake in Monument Re (“Monument” or the “Company”), a premier pan-European insurance consolidator, and support the Company’s long-term strategic growth plan. Hannover Re will continue as a key shareholder and remains committed to Monument and Sixth Street’s strategy for the business moving forward.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629331268/en/

Monument is a strategic partner to the European insurance market, offering execution‑focused capabilities to acquire and manage in‑force life insurance portfolios and deliver tailored risk‑transfer and reinsurance solutions across multiple jurisdictions. This transaction will provide Monument with fresh capital and resources to accelerate its strategic initiatives and further strengthen its market position. Following closing, Monument will continue to operate as a standalone Company and will continue to service its policyholders.

“We are excited to partner with Monument and Hannover Re as we expand our global insurance footprint,” said Rohan Singhal, Partner and Head of Insurance at Sixth Street. “This investment reflects our deep conviction in the European market and our approach of partnering with strategics as a model for success. We look forward to fulfilling Monument’s potential as a leading consolidator in its core markets, while maintaining a focus on long-term security for policyholders.”

“We welcome Sixth Street’s investment in Monument and view it as an important step for the Company’s future growth and development. Hannover Re values the strong partnership with Monument and will continue to support the Company as a reinsurance partner and shareholder,” said Brona Magee, Executive Board Member for Life & Health at Hannover Re.

“Monument is excited about the support our shareholders are showing at this pivotal moment for our Company. The combined market presence and deep expertise of Sixth Street and Hannover Re put us in a fantastic position as we continue on our growth path,” said Carlo Elsinghorst, Group Chief Executive Officer of Monument Re.

Sixth Street Insurance is a premier strategic partner to leading insurers, advising on more than $125 billion of insurance company assets and making direct investments through a highly flexible global platform. Leveraging an extensive presence across North America and Europe, Sixth Street Insurance combines long‑term capital with specialist asset liability management expertise to deliver bespoke balance sheet solutions for life and P&C insurers.

The transaction is expected to close by the end of 2026 and is subject to regulatory approvals and other customary closing conditions.

Advisors

Morgan Stanley & Co. International plc acted as financial advisor, Oliver Wyman LLC acted as actuarial advisor, KPMG LLP acted as financial and tax advisor, and Cleary Gottlieb Steen & Hamilton LLP and Debevoise & Plimpton LLP acted as legal advisors to Sixth Street. Fenchurch Advisory Partners acted as financial advisor to Monument Re, while Hogan Lovells International LLP, Conyers Dill & Pearman Bermuda, and Herbert Smith Freehills Kramer LLP acted as legal advisors.

About Sixth Street

Sixth Street is a global investment firm with over $130 billion in assets under management and committed capital. The firm uses its long-term capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Founded in 2009, Sixth Street has more than 750 team members including approximately 300 investment professionals around the world.¹ For more information, and additional disclosures, visit www.sixthstreet.com, and follow Sixth Street on LinkedIn.

About Hannover Re

Hannover Re is one of the world’s leading reinsurers. It transacts all lines of property & casualty and life & health reinsurance and is present worldwide with around 4,000 employees. German property & casualty business of the Hannover Re Group is written by the subsidiary E+S Rück. Established in 1966, Hannover Re is recognised as a reliable partner for innovative risk solutions, strong client relationships and financial soundness. The rating agencies most relevant to the insurance industry have awarded both Hannover Re and E+S Rück outstanding financial strength ratings: Standard & Poor’s AA- “Very Strong” and A.M. Best A+ “Superior”.

About Monument Re

Monument Re is a life insurance and reinsurance company focused on the acquisition and management of in‑force life insurance portfolios across Europe. The company is committed to reliable policy servicing and tailored capital solutions for insurers and institutional clients. For more information, visit www.monumentregroup.com.

¹Total Sixth Street employees as of 3/31/2026

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629331268/en/

Contacts

For Monument Re: info@monumentregroup.com
For Sixth Street: media@sixthstreet.com

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes

STAMFORD, CT–(BUSINESS WIRE)– Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

“FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” said Stacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adults have access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the continuum of risk and communicating those findings transparently.”

The FDA’s action highlights a stark contrast: in the U.S., nicotine products undergo detailed scientific review before being authorized, while in many countries policymakers opt for bans rather than careful evaluation.

Products covered by the FDA’s MRTP orders include:

ZYN Cool Mint 3 mg

ZYN Cool Mint 6 mg

ZYN Peppermint 3 mg

ZYN Peppermint 6 mg

ZYN Spearmint 3 mg

ZYN Spearmint 6 mg

ZYN Wintergreen 3 mg

ZYN Wintergreen 6 mg

ZYN Citrus 3 mg

ZYN Citrus 6 mg

ZYN Coffee 3 mg

ZYN Coffee 6 mg

ZYN Cinnamon 3 mg

ZYN Cinnamon 6 mg

ZYN Smooth 3 mg

ZYN Smooth 6 mg

ZYN Chill 3 mg

ZYN Chill 6 mg

ZYN Menthol 3 mg

ZYN Menthol 6 mg

In January 2025, ZYN was the first nicotine pouch authorized for sale in the United States following rigorous scientific review. With today’s decision, PMI holds MRTP authorizations for ZYN, the first nicotine pouch authorized by the FDA, versions of IQOS devices and consumables and eight General snus products, underscoring the company’s position as an industry leader and innovator.

EDITOR’S NOTE

• FDA has authorized the ZYN MRTP claim, effective immediately.

• From the FDA Modified Risk Granted Order: “Based on our review of your MRTPAs, we determined that the proposed modified risk tobacco products, as described in your applications and specified in Appendix A, have satisfied the requirements of section 911(g)(1)(A) and (B), including that they, as actually used by consumers, would significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products. Therefore, we authorize marketing of the tobacco products as modified risk tobacco products with the following modified risk information: ‘Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.’”

• Nicotine pouches, like ZYN, deliver nicotine through oral absorption and do not require the burning of tobacco, or inhaling of smoke. This significantly reduces exposure to harmful and potentially harmful chemicals compared to the use of combustible tobacco, such as cigarettes.
• In authorizing ZYN through the premarket tobacco product application (PMTA) pathway in January 2025, the FDA noted: “the agency’s evaluation showed that, due to substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, such as moist snuff and snus, the authorized products [ZYN] pose lower risk of cancer and other serious health conditions than such products. The applicant also provided evidence from a study showing that a substantial proportion of adults who use cigarette and/or smokeless tobacco products completely switched to the newly authorized nicotine pouch products.”

• When reviewing the ZYN applications, FDA considered extensive data showing that some adults who smoke and have started using ZYN products have reduced their cigarette use over time, with over half of those surveyed reporting no cigarette consumption in the past 30 days. Of those who continue to smoke cigarettes after starting to use ZYN products, the majority (80.7%) reduced their cigarette consumption, and over half (57.2%) reduced their cigarettes per day by more than 50%.

Philip Morris International: A Global Smoke-Free Champion

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 43% of PMI’s first-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables – the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables, General snus and ZYN also obtained the first-ever Modified Risk Tobacco Product authorizations in their respective categories from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas.

References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

About PMI U.S.: Invested In America

Philip Morris International Inc.’s U.S. businesses are invested in America’s future and advancing a smoke-free nation. The businesses are committed to providing the approximately 25 million legal-age consumers who smoke cigarettes with better, smoke-free alternatives and to ensuring the products are marketed responsibly. From PMI’s global headquarters in Stamford, Connecticut, and other locations nationwide, PMI U.S. contributes leadership, jobs, investment, and innovation in the U.S. The U.S. businesses employ more than 3,000 people across America and operate product manufacturing facilities, including in Aurora, Colorado, Owensboro, Kentucky, and Wilson, North Carolina. For more information, please visit www.uspmi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630053034/en/

Contacts

Corey Henry

Philip Morris International

T. +1 (202) 679 7296

E. corey.henry@pmi.com

Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around

TORONTO & OXFORD, England–(BUSINESS WIRE)– Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America.

Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick’s strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-commercial experience.

“We are beyond proud to join forces with Chris, Richard, and the entire team at Oxford PharmaGenesis as we focus on helping life sciences clients think holistically about how evidence, medical strategy, access considerations, and stakeholder engagement connect across the lifecycle with a scientific-to-commercial offering that unlocks the true potential of their innovations,” said Leerom Segal, Klick’s Co-Founder and Chairman. “From the moment we met, we were struck by all the commonalities we share and how rare it is for two organizations’ independence, work ethic, ethos, and histories to mirror each other quite like ours. We think it’s an important distinction that will set clients and team members up for success.”

Oxford PharmaGenesis CEO Chris Winchester said, “At Oxford PharmaGenesis, we are always looking for ways to bring the very best to our clients and create outstanding opportunities for our people. Joining Klick Health will ensure that we remain at the cutting edge of HealthScience communications but, more importantly, our shared values ensure a bright future together.”

COO Richard White added, “This is the story of two successful companies growing strongly by themselves, driven by a desire to give clients what they are going to need next, and realizing that we could achieve that better together. We are excited to continue building on our unrivaled heritage and unlocking new possibilities for our clients and our people.”

Bonded by Breakthroughs

With the growing importance of converging medical and commercial communications, as healthcare professionals, payers, and brands prioritize medical content, and large language models (LLMs) increasingly elevate content from highly authoritative, valued sources, such as peer-reviewed journal articles, Klick and Oxford PharmaGenesis are uniquely equipped with the proven scientific leadership, business models, and track records to meet these industry changes head on.

Together, they will focus on helping life sciences clients accelerate their commercial success through complementary medical and commercial strategies, seamless global execution, and almost 60 years of combined experience as trusted agency partners.

The move builds on Klick’s continued momentum in the industry and significantly deepens its scientific expertise, notably in therapeutic areas like oncology and rare diseases, while expanding its real-world evidence (RWE) and health economics and outcomes research (HEOR) capabilities. It also expands Klick’s global reach and reinforces its commitment to serve as the world’s largest, most comprehensive medical marketing agency with unsurpassed scientific-to-commercial capabilities to help global life sciences clients solve their most pressing go-to-market challenges. For Oxford PharmaGenesis, it provides clients with access to state-of-the-art technology, global award-winning creativity, and new opportunities for continued growth and innovation.

With more than 300 advanced degree holders among the 500 professionals joining Klick from across Oxford PharmaGenesis teams in the UK, US, and Australia, Klick now has more advanced degree holders (over 500) than any other single healthcare agency in the world. Klick’s global presence also expands to 12 offices across North America, the UK, Australia, Brazil, and Singapore.

Klick’s Chief Medical Officer Holly Henry said, “I’m incredibly excited to help bring together two independent industry leaders united by a shared commitment to solving complex client challenges through scientific rigor, innovation, and excellence. By combining the strengths of Klick Health and Oxford PharmaGenesis, we are creating new opportunities to support our clients across every stage of the commercialization journey, from clinical development to loss of exclusivity, while delivering deeper expertise, broader capabilities, and even greater impact.”

Today’s announcement follows Klick’s ongoing momentum building out its medical and market access offerings and expanding its global presence. In 2022, it opened offices in Asia-Pacific, Europe, and Latin America and last year acquired Peregrine Market Access, bolstering its leadership in the increasingly important value, access, and reimbursement segments within the US life sciences commercialization space. Klick then acquired the Singapore operations of Ward6, an independent life sciences agency focused on healthcare professional (HCP) marketing and medical communications.

At the same time, Klick made history in 2025 by becoming the first health agency to ever be ranked an ‘Agency of the Year’ by both The One Show and New York Festivals Advertising Awards. Earlier this month, it won 48 Clio Health awards, including three Grand Clios, for creative excellence in health marketing, advertising, and communications; was named Campaign’s inaugural Global Healthcare & Pharma Agency of the Year (Gold); and was ranked Cannes Lions’ #1 Healthcare Agency, #1 Healthcare Network of the Year, and Independent Agency of the Year – Health. Klick also recently announced a vocal biomarker research collaboration with Mayo Clinic.

About Oxford PharmaGenesis

Oxford PharmaGenesis is a HealthScience communications consultancy; the largest independent company in the healthcare communications sector. Founded in 1998, the award-winning organization comprises more than 500 talented people working from North America, Europe, and Asia-Pacific.

The only company in its sector to be named a three-time winner of the King’s (formerly Queen’s) Award for Enterprise, the UK’s most prestigious business accolade, Oxford PharmaGenesis received a 2026 Longitude Prize on ALS and has been named Communique Awards’ Medical Affairs Agency of the Year; and PharmaTimes’ Medical Affairs Communications Team of the Year. In addition, the agency has consistently been recognized as a Great Place to Work in the UK, US, and Australia, as well as a Top 10 Best Workplace for Women and a Centre of Excellence in Wellbeing.

Oxford PharmaGenesis enjoys a strong company culture and a clear mission: to help clients to accelerate adoption of evidence-based innovations for patients in areas of unmet medical need. Learn more about Oxford PharmaGenesis at https://www.pharmagenesis.com/.

About Klick Health

Klick Health is the world’s largest independent commercialization partner for life sciences, focused on hacking the boundaries of health by developing, launching, and supporting life sciences brands to achieve their full potential. The agency provides best-in-class marketing and advertising, media strategy and purchasing, medical affairs and medical communications, value and market access services, as well as technology and analytics consulting among its specialized offerings. Klick’s client service is rooted in deep medical and scientific understanding, enabled by nearly 250 post-graduate, in-house medical experts; unrivaled decision sciences capabilities; and innovative, results-driven creative.

One of the most-awarded advertising agencies on the planet, Klick has been ranked a Best Managed Company, Great Place to Work, Best Workplace for Women, Best Workplace for Inclusion, Best Workplace for Professional Services, Most Admired Corporate Culture, and a FORTUNE Best Workplace in Advertising. Klick was also named Cannes Lions’ 2026 Healthcare Agency of the Year,Healthcare Network of the Year, and Independent Agency of the Year – Health, along with Campaign’s inaugural Global Healthcare and Pharma Agency of the Year, Clio Health Independent Agency of the Year for the last four years, and 2025 London International Awards Global (and Regional) Independent Health & Pharma Agency of the Year. Last year, the company made history by becoming the first health agency to ever be ranked an Agency of the Year by both The One Show and New York Festivals Advertising Awards.

Established in 1997, Klick Health (including Klick Katalyst and btwelve) has offices in New York, Philadelphia, Saratoga Springs, Toronto, London, São Paulo, and Singapore. It is part of the Klick Group of companies, which also includes Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, and Klick Ventures. Follow Klick Health on LinkedIn and for more information on joining Klick, go to careers.klick.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630989799/en/

Contacts

Press Contact
For more information, please contact Klick PR at pr@klick.com or (416) 214-4977.

LONDON–(BUSINESS WIRE)– Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/

Hytera’s latest SC700 Smart 4G Body Camera

Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams.

It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or device tampering, and automatically alert dispatch centers.

“The role of body-worn camera is evolving beyond evidence capture,” said Leslie Li, Deputy General Manager of BWC Business Unit, Hytera. “It is becoming part of a connected operational workflow that links frontline personnel, control rooms, and decision-makers in real time.”

Designed for frontline use, the SC700 combines a long battery life, simple operation, and secure evidence handling, supporting organizations in improving situational awareness and operational response.

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of critical communications technologies and solutions. Hytera has been serving worldwide users over three decades with its innovative portfolio of two-way radios, PMR&LTE convergent communications, fast-deploy communications, body-worn camera, control room, etc. Learn more at https://www.hytera.com/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630283236/en/

Contacts

lele.yao@hytera.com

COURBEVOIE, France–(BUSINESS WIRE)– Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy.

The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees.

This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses.

A key milestone in LEAP | 28 portfolio rotation

This transaction represents a significant milestone in Bureau Veritas’ portfolio transformation. Following completion and taking into account other recent acquisitions year-to-date, the Group will have executed approximately 20% portfolio rotation since the launch of LEAP | 28.

“This divestment is fully aligned with our LEAP | 28 strategy and our commitment to actively manage our portfolio,” said Hinda Gharbi, Chief Executive Officer of Bureau Veritas. “The Oil & Petrochemicals and Coal business operates in established and mature markets, and is led by a global team. Under the leadership of Triton Partners, we are confident that this business will continue to develop successfully. This transaction will create shareholders value as Bureau Veritas accelerates its planned portfolio pivots towards higher growth and higher margin activities.”

The transaction, based on an enterprise value of EUR 470 million, implies an EV/EBIT multiple of 11.1x on 2025 results post IFRS16. The disposal will have a positive impact on the Group’s organic growth profile, adjusted operating margin and return on capital employed. The deal is anticipated to be broadly neutral to earnings after closing.

Bureau Veritas intends to redeploy the proceeds towards higher-growth and higher-margin businesses, in line with LEAP I 28 portfolio ambitions.

Transaction terms and timetable

This contemplated transaction, currently under negotiation, will be subject to information and consultation procedures with the relevant employee representative bodies, and could be finalized by the end of Q1 2027, subject to the fulfillment of customary conditions precedent.

***

About Bureau Veritas:

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.

Our information is certified with blockchain technology.

Check that this press release is genuine at www.wiztrust.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260628184468/en/

Contacts

ANALYST/INVESTOR CONTACTS

Laurent Brunelle
+33 (0) 7 79 52 69 21

laurent.brunelle@bureauveritas.com

Colin Verbrugghe
+33 (0) 6 80 53 26 72

colin.verbrugghe@bureauveritas.com

Romain Gorge
romain.gorge@bureauveritas.com

Inès Lagoutte
ines.lagoutte@bureauveritas.com

MEDIA CONTACTS

Karine Havas
+33 (0) 6 68 63 83 18

karine.havas@bureauveritas.com

Frédéric Vallois
+33 (0) 6 21 66 31 04

frederic.vallois@bureauveritas.com

Leading French multi-family office with approximately US$5 billion in assets is Corient’s fourth European acquisition, growing firm’s global assets to approximately US$523 billion

MIAMI & PARIS–(BUSINESS WIRE)– Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe.

The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients.

Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion).

Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke services that integrate all aspects of wealth management and family office functions, including investment management, wealth and estate planning, financing, legal and tax support, and philanthropy. Letus is further differentiated by its ability to structure complex asset-based transactions – including real estate, art, hotels, vineyards, farms, aircraft, yachts and other property – by providing project management and assistance with financial and legal advice.

“Letus has built a dynamic and entrepreneurial firm that is redefining what exceptional family office service looks like for successful families and business owners,” said Kurt MacAlpine, Founding Partner and Chief Executive Officer of Corient. “Their talented team and deep relationships in the French market make them a perfect fit for our partnership. We are excited to welcome them to Corient.”

“Since our founding, our goal has been to build a different kind of family office – one that combines deep expertise with a highly personal approach to serving clients,” said Alexandre Tsouli. “With Corient, we have found a true partner who shares those values while providing extensive resources and global reach that will enable us to do more for clients. We are excited to join Corient as Partners.”

“I have known the founders of Letus for many years and am delighted they are becoming Corient Partners,” said Daniel Pinto, Corient Partner and CEO, EMEA. “They have built an entrepreneurial firm that reflects the growing demand in France for independent wealth advice beyond the traditional banking model, making them an ideal fit for our partnership. The Letus team will considerably expand our existing capabilities in France, a key market in which we have been active for a number of years.”

Upon closing, Letus principals will become Corient Partners. The Corient partnership model is the firm’s defining advantage, designed to foster seamless collaboration across the firm and deliver the full strength of the firm’s capabilities to help clients navigate the complexities of significant wealth.

This transaction is the latest development in Corient’s global expansion. Earlier this year, Corient completed the acquisitions of Stonehage Fleming and Stanhope Capital Group, establishing a presence across Europe, the Middle East and Africa. Corient has also agreed to acquire Bedrock Group, a Geneva-based multi-family office managing approximately US$10 billion in client assets.

Corient, established in 2020, operates under a client-first approach with complete fee transparency. Corient is distinguished in wealth management by its private partnership model, similar to those used by leading professional services firms. The structure gives clients access to the full breadth of expertise and resources across Corient rather than depending on a single advisor. Since its founding, Corient has grown to include more than 300 partners and over 2,500 employees managing approximately US$523 billion globally on behalf of ultra-high- and high-net-worth individuals, families and businesses.

About Corient

Corient is the world’s largest multi-family office and non-bank wealth manager focused on serving ultra-high- and high-net-worth clients. As the industry’s only global professional services partnership, we combine the personal service and objectivity of a boutique with the scale and resources of a global institution. Our partnership model fosters collaboration over competition, bringing together the collective expertise of Corient to each relationship to deliver a transparent, client-first experience. As a fully integrated global firm, we deliver comprehensive solutions across investment management, wealth strategy and family office services to help clients simplify their lives, manage their wealth and establish lasting legacies. For more information, visit corient.com.

Corient refers to affiliated entities under common control of Corient Global HoldCo Limited.

Corient client assets reflect the aggregate assets of Corient Global HoldCo Limited (“HoldCo”) and include assets in which HoldCo has a majority or minority ownership interest, as well as assets from transactions that have been signed, but not yet closed and are subject to regulatory approvals. Firm assets related to HoldCo are current as of May 31, 2026. Firm statistics, including partner and employee headcount, are as of June 1, 2026. Letus assets are as of December 31, 2025. Bedrock assets are as of March 31, 2026. Data reflect varying as of dates due to differing reporting cycles. Services are provided only in jurisdictions where authorized and may not be available in all locations or for all client types.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629775534/en/

Contacts

Jimmy Moock

Managing Partner, StreetCred

610-304-4570

jimmy@streetcredpr.com
corient@streetcredpr.com